VELCADE® (bortezomib) for Injection

VELCADE is approved in more than 90 countries, including the United States and countries in the European Union.

Janssen has ex-U.S. commercialization rights to VELCADE. Click here to visit the company's website.

US Healthcare Providers
Please click here for the Product Website and click here for the Full Prescribing Information.

Ex-US Healthcare Providers
Please click here for the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information.